Pharmaceutical / Pharmaceuticals / Drug / Drugs / Medicine / National blog main / National top stories / New York / New York blog main / New York top stories / San Diego blog main / Autoimmune Diseases / Biogen / Biotech / Bristol-myers Squibb / Celgene / clinical trials / coronavirus / COVID-19 / Crohn's Disease / FDA / fingolimod / Interferon-beta / Life Sciences / Multiple Sclerosis / Novartis / ozanimod / siponimod / ulcerative colitis

FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch

Posted On: Mar 26, 2020   |   Posted By: Xconomy

FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch

A multiple sclerosis drug that came to Bristol Myers Squibb via its acquisition of Celgene last year was approved Thursday but don't expect it to reach patients any time soon. The company says the drug's launch will be delayed due to the coronavirus pandemic. The Bristol drug, ozanimod , is one of the medicines approaching commercialization that the pharmaceutical giant touted as justification for its $74 billion buyout of Celgene. Some analysts have projected that the drug could become a blockbuster seller. But when ozanimod does reach the market, it will compete against other MS medicines in...

Continue reading ...